[1] |
HU Xi’e , YANG Zhenyu , XUE Jingyi , YANG Ping , PENG Shujia , YUAN Lijuan , BAO Guoqiang .
Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer
[J]. China Oncology, 2021, 31(3): 221-226.
|
[2] |
JIANG Mengyi , LU Yanqiao , WANG Hongxia .
Research progress and clinical significance of breast cancer heterogeneity
[J]. China Oncology, 2020, 30(5): 394-400.
|
[3] |
SHI Zhiqiang , QIU Pengfei , LIU Yanbing , ZHAO Tong , SUN Xiao , CHEN Peng , WANG Chunjian , ZHANG Zhaopeng , CONG Binbin , WANG Yongsheng .
Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer
[J]. China Oncology, 2020, 30(3): 186-191.
|
[4] |
CAO Xiaoshan, CONG Binbin.
The progress of treatment for triple-negative breast cancer in the era of precision medicine
[J]. China Oncology, 2019, 29(12): 971-976.
|
[5] |
ZHENG Xiaying, CHEN Junxia.
Expression of circRNA hsa_circ_0005320 in triple-negative breast cancer and its effect on cell proliferation
[J]. China Oncology, 2019, 29(11): 845-854.
|
[6] |
ZHU Xiuzhi, CHEN Li, JI Lei, GAO Yu, WANG Zhonghua.
Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors
[J]. China Oncology, 2019, 29(11): 899-905.
|
[7] |
YANG Rui, CHEN Junxia.
Effects of circular RNA hsa_circ_0058514 on the development and progression of triple-negative breast cancer
[J]. China Oncology, 2019, 29(1): 9-18.
|
[8] |
LI Jiawei, SHI Zhaoting, HOU Yingmin, et al.
Clinicopathological and immunohistochemical basis for sonographic characteristics of triple-negative invasive breast cancer
[J]. China Oncology, 2019, 29(1): 37-44.
|
[9] |
XU Fengling, HUANG Xianyu, WANG Linna.
The effects of secretory clusterin on oxidative damage in MIA PaCa-2 cells treated by gemcitabine and preliminary mechanism of resistance to gemcitabine
[J]. China Oncology, 2018, 28(2): 111-116.
|
[10] |
JI Peng, GONG Yue, DI Genhong.
Latest research progress on tumor-infiltrating lymphocytes in HER2-positive and triple-negative breast cancer
[J]. China Oncology, 2018, 28(12): 928-934.
|
[11] |
LIU Zimei, YU Wenxi, SUN Chu, et al.
Clinical significance of ICAM-1 expression and its correlation with prognosis of triple-negative breast cancer
[J]. China Oncology, 2017, 27(2): 121-127.
|
[12] |
LIU Zimei, SHEN Zan.
The latest developments in targeted therapy for triple-negative breast cancer
[J]. China Oncology, 2017, 27(1): 36-40.
|
[13] |
SUN Chu, LI Hongtao, LIU Zimei, et al.
The influence of diagnostic interval and other clinicopathological factors on the prognosis of triplenegative breast cancer
[J]. China Oncology, 2016, 26(6): 538-545.
|
[14] |
JIANG Weihua, LI Yongtao, WANG Xiaowen, et al.
The differences in expressions of EGFR and VEGF between Han and Uygur triple-negative breast cancer patients
[J]. China Oncology, 2016, 26(5): 404-408.
|
[15] |
LIU Xiaoli, JIANG Da, CUI Yanzhi.
Research progress on androgen receptor in triple-negative breast carcinoma
[J]. China Oncology, 2016, 26(5): 466-470.
|